Sulfur inhibits the growth of androgen-independent prostate cancer in vivo

FEI DUAN1, YUHUA LI2,3, LIANGKANG CHEN2, XIAOYU ZHOU2, JIANXING CHEN2, HAILIN CHEN2 and RUNSHENG LI2

1Shanghai Medical College, Fudan University; 2Key Laboratory of Contraceptive Drugs and Devices of NPFPC, Shanghai Institute of Planned Parenthood Research, Shanghai 200032; 3Department of Pathophysiology, Prostate Diseases Prevention and Treatment Research Center, Norman Bethune College of Medicine, Jilin University, Jilin 130021, P.R. China

Received March 6, 2014; Accepted September 8, 2014

DOI: 10.3892/ol.2014.2700

Abstract. Sulfur is a bright yellow crystalline solid at room temperature. The aim of the present study was to investigate the inhibitory effect of sulfur on prostate cancer (PCa) in vivo. Prostate tumors were developed by injecting 22Rv1 or DU-145 PCa cells into sulfur-treated or untreated nude mice. The weight and volume of the tumors were measured. The cancer cells were separated from the tumors, and analyzed for their growth rate and clonogenicity in culture. The expression of PCa-targeted genes was also assessed using real-time polymerase chain reaction. The rate of growth of 22Rv1 tumors in sulfur-treated nude mice gradually decreased, and was reduced by 41.99% (P<0.01) after 22 days when compared with that of the control group. In addition, the growth of DU-145 tumors was also suppressed by 75.16% (P<0.05) after 11 weeks. The clonogenicity of the sulfur-treated tumor cells decreased by 36.7% when compared with that of the control cells. However, no significant difference in cell growth was identified. mRNA levels of the androgen-receptor, prostate specific antigen and human Hox (NKX3.1) genes were significantly decreased by 32.8, 48.2 and 42.2% in sulfur-treated tumors, respectively. Additionally, it was found that the hydrogen sulfide concentration in the serum of sulfur-treated mice was increased by 4.73% (P<0.05). Sulfur significantly suppressed the growth of PCa in vivo. Since sulfur is a known ingredient used in traditional Chinese medicine, it may be used clinically for the treatment of PCa, independently or in combination with other medicine.

Introduction

Sulfur is bright yellow crystalline solid or powder material. In traditional Chinese medicine (TCM), sulfur is widely used for detoxifying the body and the treatment of scabies (1,2), healing sores and itching (3). It was confirmed by United States Pharmacopeia that sublimed sulfur and subsided sulfur may be used as drugs (4). When absorbed by the skin, sulfur is metabolized to inorganic sulfide or organic sulfocompounds, and it is involved in metabolism in vivo (5). Recently, studies have reported that sulfocompounds inhibit cancer cell growth. For example, GYY4137, a sulfocompound, caused the concentration-dependent killing of various cancer cell lines (6), and S-propargyl-cysteine exhibited anticancer effects on gastric cancer cells (7). Furthermore, Allicin, which contains diallyl disulfide, reduced the risk of a variety of malignant tumors, including different glioblastoma cells (8) and hepatocellular carcinoma (9) in vitro, and osteosarcoma cells in vitro and in vivo (10,11).

Prostate cancer (PCa) is the most common malignancy of the male genitourinary system. Since Huggins first treated PCa by androgen deprivation treatment (ADT) (12), ADT has been widely used for PCa treatment. Initially, PCa responds to androgen ablation and disease progression slows down. However, the androgen ablation is palliative, and the disease eventually ensues (13). PCa recurs and the surviving cancer cells become androgen-independent. At this stage, tumors are more aggressive and usually fatal, and hormone blockade therapy fails (14). At present, no effective therapy method has been identified for recurrent PCa and only traditional treatments are primarily used to provide symptomatic benefits, and identifying new methods to treat androgen-independent PCa has been a new area of focus for researchers (15). Recently, the pathways mediated by an androgen receptor (AR) or to bypass ARs have been researched in recurrent PCa, additionally treatment pathways and novel therapies have been investigated to PCa therapy with this potential target Recently, the pathways mediated by an androgen receptor (AR) or to bypass ARs have been researched in recurrent PCa (16,17). Additionally treatment pathways and novel therapies have been investigated for PCa therapy with this potential target (18,19). 22Rv1 is an
androgen-independent PCa epithelial cell line, which grows independently of androgen, and is representative of clinical recurrent PCa. However, 22Rv1 cells express the AR and react with androgens (20). Previous studies have shown that the progression of androgen-independent PCa is independent of the androgen, but dependent on the AR signaling pathway (21). 22Rv1 cells also secrete prostate-specific antigen (PSA) (22), which is often used to evaluate the efficiency of PCa treatment. DU-145 and PC-3 cell lines are also androgen-independent PCa cell lines and, thus, are often used in the study of PCa. The two cell lines do not express AR and PSA (23), while the majority of clinical PCa cases significantly express the two genes.

In the present study, 22Rv1 and DU-145 prostate tumors were developed in nude mice and the aim of the study was to investigate the inhibitory effect of sulfur on prostate cancer cells.

Materials and methods

Drugs and animals. Sulfur powder with a purity of ≥99% was purchased from the Shanghai Chemical Reagent supply station and mixed with milk powder (Nestlé S.A., Vevey, Switzerland) at 1:30 (w/w).

Specific pathogen-free (SPF) male BALB/c nude mice aged between six and eight weeks (weight range, 18-25 g) were purchased from Shanghai SLAC Laboratory Animal Co., Ltd., [License Number, SCXK (Shanghai) 2007-0002; Shanghai, China], and fed under SPF conditions. Mice in the 22Rv1 and DU-145 experiments were randomly divided into two groups, control and sulfur-treated groups, with 10 mice in each group. Ethical approval for the study was obtained from the Animal Ethics committee of Shanghai Institute of Planned Parenthood Research (Shanghai, China).

Cell culture. 22Rv1 cells were purchased from Shanghai Institute of Cell Life Sciences Resource Center (Shanghai, China). The cells were maintained in RPMI-1640 medium (HyClone; Thermo Fisher Scientific, Rockford, IL, USA) containing 50 ml/l fetal bovine serum (FBS; Gibco-BRL, Carlsbad, CA, USA), 100,000 units/l penicillin and 100 mg/l streptomycin, at 37°C with an atmosphere of 5% CO2.

Xenograft tumor development in nude mice. 22Rv1 cells and DU-145 cells were harvested at the exponential growth stage, washed and suspended in phosphate-buffered saline (PBS). The cells were counted, and the cell suspension was subcutaneously injected into the flanks of mice with 2x10⁶ cells in 0.1 ml PBS. A Trypan-blue exclusion assay was performed to ensure cell viability (>99%) prior to inoculation.

Each mouse in the sulfur-treated group was provided with 0.62 g/day sulfur-milk powder one day following inoculation with 22Rv1 and DU-145 cells, while mice in the control group were provided with milk powder. Tumor size was measured in two diameters every other day (22Rv1 tumor) or every week (DU-145 tumor). Tumor volume (cm³) was calculated using the following formula: Tumor volume = a²b/2 (a, longer diameter; b, shorter diameter).

Following the experiment, mice with 22Rv1 tumors were narcotized with 0.2 ml 1% sodium pentobarbital and blood was then collected from the heart. Tumors were dissected and weighed.

Cells separation from 22Rv1 tumors. 22Rv1 tumors were cut into sections between 1 and 2 mm³, and tumor sections in the same group were mixed, washed with cold PBS containing 200 units/ml penicillin and 200 mg/l streptomycin, digested with trypsin for 5 min at 37°C, and then the digested cells were suspended by RPMI-1640 medium with 5% FBS. The cell suspension was filtrated using a 200-mesh sieve, and then centrifuged at 175 x g for 5 min. The supernatant was then discarded and the cells were suspended with fresh medium, and incubated at 37°C in an atmosphere of 5% CO2.

Clone-forming capability of tumor cells. A total of 300 tumor cells from the sulfur-treated and control groups were seeded, respectively, into 24-well plates in RPMI-1640 medium and incubated for two weeks. The medium was then discarded, cell clones were washed three times with PBS, fixed with 5% formaldehyde for 20 min, stained with crystal violet solution for 5 min, washed for several times, dried and counted.

The cell growth of the tumor cells was measured using the MTT method demonstrated by Meletiadis et al (21).

Analysis of gene expression by quantitative polymerase chain reaction (qPCR). Total RNA was extracted using TRIzol reagent (Invitrogen Life Technologies, Inc., Carlsbad, CA, USA) according to the manufacturer's instructions. Total RNAs in the same group were mixed in the same quantity. First-strand cDNA was synthesized from 2 μg of RNA mixture using Quant Reverse Transcriptase (Toyobo Co., Ltd., Osaka, Japan). Gene expression in 22Rv1 tumors was measured using qPCR. The sequences of the primers used are shown in Table I.

Hydrogen sulfide (H2S) levels in mice serum. Blood was collected from the hearts of the mice and the serum was separated. H2S levels in the serum were analyzed using the mouse serum H2S Elisa kit according to the manufacturer's instructions (Shanghai Feng Xiang Biological Technology Co., Ltd., Shanghai, China).

Statistical analysis. Data were analyzed using SPSS software, version 11.5 (SPSS, Inc., Chicago, IL, USA). The continuous variables of tumor weight, tumor volume and H2S level were compared using one-way analysis of variance. Consequently, the analyzed results are presented as the mean ± standard deviation (SD). In addition, the clones were also presented as the mean ± SD. P<0.05 was considered to indicate a statistically significant difference.

Results

Sulfur inhibits the growth of 22Rv1 and DU-145 tumors. Approximately eight days following inoculation of the 22Rv1 cells, the tumor sizes were measurable (Fig. 1A). The growth of the tumors obtained from sulfur-treated mice gradually slowed down, and a significant difference was identified 18 days following inoculation when compared with that of the control group. The mean tumor volume of
The sulfur-treated group was 0.35±0.12 cm³ after 22 days, which was 41.99% smaller than that of the control group (0.61±0.28 cm³) (P<0.01; Fig. 1B). The mean tumor weight of the sulfur-treated group was 0.25±0.10 g, which was significantly decreased by 41.78% when compared with that of the control group (0.43±0.13 g) (P<0.05; Fig. 1C). The mean body weights of the tumor-bearing mice were 21.11±1.62 and 24.91±1.56 g in the sulfur-treated and control groups, respectively. However, no significant difference in body weight was identified. The results demonstrated that sulfur significantly inhibits the growth of 22Rv1 tumors in vivo.

DU-145 tumors were measurable five weeks following inoculation, and the growth of tumors of the sulfur-treated group gradually slowed down and a significant difference was identified eight weeks after inoculation, when compared with that of the control group. The mean tumor volume of the sulfur-treated group was 0.41±0.30 cm³ 11 weeks after inoculation, which was 75.16% smaller than that of the control group (1.64±1.34 cm³) (P<0.05; Fig. 1D). The results demonstrated that sulfur significantly inhibits androgen-independent prostate tumor growth.

Since 22Rv1 cells, but not DU-145 cells, express AR and PSA, 22Rv1 tumors were selected for further study.

Table I. Primers used for qPCR.

| Gene      | Primer sequences                  | Annealing temperature (˚C) | Product length (bp) |
|-----------|-----------------------------------|-----------------------------|---------------------|
| β-actin   | F: 5'-CCTGTACCGCAACACAGTGC-3'    | 58                          | 211                 |
|           | R: 5'-ATACTCCTGTTGCTGATCC-3'     |                             |                     |
| AR        | F: 5'-TTCCCTCCTATCCTACCCCTC-3'   | 58                          | 202                 |
|           | R: 5'-TCTAAACTCCTCCGTGCCATAA-3'  |                             |                     |
| PSA       | F: 5'-AGTCTGCGGTGGTTCTCT-3'      | 58                          | 139                 |
|           | R: 5'-GTGGCTGACCTGAAATACCTG-3'   |                             |                     |
| NKX3.1    | F: 5'-AGAAGGCACTTGGGGTCTT-3'     | 60                          | 210                 |
|           | R: 5'-TCCGTAAGCTTAGTTCTT-3'      |                             |                     |

F, forward; R, reverse; bp, base pairs; AR, androgen receptor; PSA, prostate specific antigen; qPCR, quantitative real-time polymerase chain reaction.

Figure 1. Sulfur inhibits the growth of PCa tumors. (A) A total of 2x10⁶ 22Rv1 or DU-145 cells were inoculated in the flank of each nude mouse. Tumor volumes were measured at the indicated times. (B) Growth of 22Rv1 tumors gradually slowed and showed a significant decrease 18 days following inoculation (C) 22Rv1 tumor weights were measured 22 days following inoculation. (D) Growth of DU-145 tumors significantly decreased after eight weeks following inoculation. *P<0.05 and **P<0.01.

Sulfur decreases the clonogenicity of 22Rv1 tumor cells. In order to further investigate the inhibitory effects of sulfur on PCa tumor growth in vivo, 22Rv1 cells were separated from the xenograft tumors, and maintained in culture for at
least two weeks prior to their application in the following approach. A total of 200 cells from each group were seeded in 24-well plates, respectively, and incubated to form clones (Fig. 2A). Cells from the sulfur-treated tumors formed 44.00±1.41 clones per well, which was 36.69% less than that of the control tumors (69.50±2.12 clones per well) (Fig. 2B), indicating that the clonogenicity of 22Rv1 PCa cells was significantly decreased by sulfur.

In addition, the inhibition of 22Rv1 tumor growth was maintained when sulfur was removed. The MTT method was used to measure the growth rate of 22Rv1 tumor cells; however, no significant difference was identified between cells from the two groups (Fig. 2C).

**Sulfur inhibits the expression of AR, PSA and NKX3.1 in 22Rv1 tumors.** AR is involved in PCa progression (21), and is expressed in 22Rv1 cells, in addition to AR-regulated genes PSA (25) and NKX3.1 (26). The expression of these genes was analyzed using qPCR. As shown in Fig. 3, the expression of AR, PSA and NKX3.1 were significantly decreased in sulfur-treated tumors by 32.8, 48.2 and 42.2%, respectively (Fig. 3A). These results indicated that the downregulation of the AR signaling pathway contributes to the inhibitory effect of sulfur on PCa growth in vivo.

**Sulfur marginally increases H₂S levels in mice serum.** Mice serum H₂S levels were measured by ELISA. The H₂S level in sulfur-treated mice was marginally increased by 4.73% (237.46±8.40 pg/ml) in the sulfur-treated group compared with 226.74±3.18 pg/ml in the control group (Fig. 3B), and a significant difference was identified. The results indicated that sulfur marginally increases H₂S levels in mice serum.

**Discussion**

The present study demonstrated that sulfur significantly inhibits PCa growth in xenograft models (Fig. 1). In previous studies, inorganic sulfur has been demonstrated to inhibit the cell proliferation of breast cancer cells in vitro when dissolved in methanol, which is toxic to the body and difficult to use in vivo (27). As sulfur is not dissolved in water saline solution, it cannot be used directly for the evaluation of its anticancer effects in cell culture. In the present study, clone-forming analysis of cells separated from tumors also demonstrated the inhibitory effect of sulfur on cancer cells (Fig. 2A), and possibly contributed to its inhibitory effect observed in vivo. However, no significant inhibitory effect of sulfur was identified on the growth of tumor cells in the present study. The anticancer effect of sulfur may be temporary, as the growth of tumor cells was inhibited only in the environment of sulfur in vivo. In our study, tumors were removed from the sulfur-treated mice and the anticancer effect of sulfur was diminished. However, cells with a lower growth rate may be eliminated during long term culturing, such as in the present study.

The androgen-receptor is involved in PCa progression (21), and is an important target of numerous drugs used for PCa therapy. The present study demonstrated that sulfur significantly inhibited AR expression in 22Rv1 prostate tumors. Possibly as a result of reduced AR expression, the expression of PSA and NKX3.1, two AR-targeted genes, were also inhibited.

**Figure 2. Analysis of the clonogenicity and growth rate of tumor cells.** Tumor cells were separated from the 22Rv1 tumors, and cultured for analysis of the (A and B) clone-forming ability and (C) growth rate. All experiments were performed independently three times. (A) Representative experiment of clone-forming. (B) Number of clones. Clones from the three experiments was counted and averaged. "P<0.01 vs. the control group. (C) Analysis of growth rate revealed no significant difference between the two groups, P>0.05.

**Figure 3. Serum H₂S level and tumor gene expression in sulfur-treated mice.** (A) Sulfur inhibited the expression of AR, PSA and NKX3.1. Total RNA was prepared from tumors and the expression of AR, PSA and NKX3.1 was measured by quantitative polymerase chain reaction. "P<0.01 and ""P<0.001. (B) H₂S levels in mice serum. Mouse blood was collected from the heart and serum was isolated. H₂S levels were then measured by ELISA. "P<0.05. H₂S, hydrogen sulfide; AR, androgen receptor; PSA, prostate-specific antigen.
Glycomics for drug inhibits the H2S donor, S-propargyl-cysteine, inducing apoptosis and significantly inhibited the growth of androgen-independent tumors. The characterization of metabolites of sulfur that exhibit anticancer activity may aid the development of anti-PCa drugs.

In conclusion, the present study revealed that sulfur significantly inhibited the growth of androgen-independent tumors. Since sulfur has been used in the clinical treatment of various diseases and is also a component of TCM, this study supports the application of sulfur in the treatment of clinical PCa, particularly recurrent PCa.

Acknowledgements

This study was supported by the National Natural Science Foundation of China (grant no. 81270760) and the National Basic Research Program of China (grant no. 2014CB943104).

References

1. Pruksachatkunakorn C, Damrongsk M and Sinthupuan S: Sulfur for scabies outbreaks in orphans. Pediat Dermatol 19: 448453, 2002.
2. Kenawi MZ, Morsy TA, Abdalla KF and el Hady HM: Treatment of human scabies by sulfur and permethrin. J Egypt Soc Parasitol 23: 691-696, 1993.
3. Gupta AK and Nicol K: The use of sulfur in dermatology. J Drugs Dermatol 3: 427-431, 2004.
4. United States Pharmacopeia. USP35-NF30. The Unites States Pharmacopeia Convention, 4727, 2012.
5. Parcell S: Sulfur in human nutrition and applications in medicine. Altern Med Rev 7: 22-44, 2002.
6. Lee ZW, Zhou J, Chen CS, et al: The slow-releasing hydrogen sulfide donor, GYY4137, exhibits novel anti-cancer effects in vitro and in vivo. PLoS One 6: e21077, 2011.
7. Ma K, Liu Y, Zhu Q, et al: H2S donor, S-propargyl-cysteine, increases CSE in SGC-7901 and cancer-induced mice: evidence for a novel anti-cancer effect of endogenous H2S? PLoS One 6: e20525, 2011.
8. Das A, Banik NL and Ray SK: Garlic compounds generate reactive oxygen species leading to activation of stress kinases and cysteine proteases for apoptosis in human glioblastoma T98G and U87MG cells. Cancer 110: 1083-1095, 2007.
9. Zhang ZM, Zhong N, Gao HQ, et al: Inducing apoptosis and upregulation of Bax and Fas ligand expression by allicin in hepato-cellular carcinoma in Balb/c nude mice. Chin Med J (Eng) 119: 422-425, 2006.
10. Zeng JX, Sun JJ, Mo JC, Ma Y and He XS: Inhibition of Allicin on Growth of Neuroblastoma in Vitro and in Vivo. J. Journal of Sun Yat-Sen University (Medical Sciences) 3: 009, 2009.
11. Karmakar S, Banik NL, Patel SJ and Ray SK: Garlic compounds induced calpain and intrinsic caspase cascade for apoptosis in human malignant neuroblastoma SH-SYSY cells. Apoptosis 12: 671-684, 2007.
12. Huggins C and Hodges CV: Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941. J Urol 168: 9-12, 2002.
13. Kozlowski JM, Ellis WJ and Grayhack JT: Advanced prostatic carcinoma. Early versus late endocrine therapy. Urol Clin North Am 18: 15-24, 1991.
14. Denmeade SR and Isaacs JT: A history of prostate cancer treatment. Nat Rev Cancer 2: 389-396, 2002.
15. Petrylak DP: Current state of castration-resistant prostate cancer. Am J Manag Care 19: 358-365, 2013.
16. Chi KN, Bjartell A, Dearnaley D, et al: Castration-resistant prostate cancer: from new pathophysiology to new treatment targets. Eur Urol 56: 594-605, 2009.
17. Debes JD and Tindall DJ: Mechanisms of androgen-refractory prostate cancer. N Eng J Med 351: 1488-1490, 2004.
18. Hartel A, Didier A, Pfaffl MW and Meyer HH: Characterisation of gene expression patterns in 22Rv1 cells for determination of environmental androgenic/antiandrogenic compounds. J Steroid Biochem Mol Biol 84: 231-238, 2003.
19. Kim J and Coetzee GA: Prostate specific antigen gene regulation by androgen receptor. J Cell Biochem 93: 233-241, 2004.
20. Sramkoski RM, Pretlow TG II, Giacoma JM, et al: A new human prostate carcinoma cell line, 22Rv1. In Vitro Cell Dev Biol Anim 35: 403-409, 1999.
21. Ware JL, Paulson DF and Webb KS: 1,10-Phenanthroline reversibility inhibits proliferation of two human prostate carcinoma cell lines (PC-3 and DU145). Biochem Biophys Res Commun 124: 538-543, 1984.
22. Meletiadis J, Meis JF, Mouton JW, Donnelly JP and Verweij PE: Comparison of NCCLS and 3-(4,5-dimethyl-2-thiazyl)-2, 5-diphenyl-2H-tetrazolium bromide (MTT) methods of in vitro susceptibility testing of filamentous fungi and development of a new simplified method. J Clin Microbiol 38: 2949-2954, 2000.
23. Sardana G, Jung K, Stephan C and Diamandis EP: Proteomic analysis of conditioned media from the PC3, LNCaP, and 22Rv1 prostate cancer cell lines: discovery and validation of candidate prostate cancer biomarkers. J Proteome Res 7: 3329-3338, 2008.
24. Sciacovillo PJ, Abrams EW, Yang L, Austenberg LP, Shen MM and Abate-Shen C: Tissue-specific expression of murine Nkx3.1 in the male urogenital system. Dev Dyn 209: 127-138, 1997.
25. Ha AW, Hong KH, Kim HS and Kim WK: Inorganic sulfur reduces cell proliferation by inhibiting of ErbB2 and ErbB3 protein and mRNA expression in MDA-MB-231 human breast cancer cells. Nutr Res Pract 7: 89-95, 2013.
26. Qin X, Zhang H, Yao X, et al: Variations in circulating sex steroid levels in metastatic prostate cancer patients with combined androgen blockade: observation and implication. Andrology 1: 512-516, 2013.
27. Nishimura S, Hato M, Hyugaji S, et al: Glycomics for drug discovery: metabolic perturbation in androgen-independent prostate cancer cells induced by unnatural hexosamine mimics. Angew Chem Int Ed Engl 51: 3386-3390, 2012.